Is big pharma really on cusp of AI shake-out?
Artificial intelligence could herald a new era for drug development but caution remains about how revolutionary its impact will actually be GlaxoSmithKline’s $43m deal with British AI firm Exscientia may signal a revolution for drug development that could radically speed up the drug discovery process, helping patients in urgent need of specialist treatments. Other leading pharma giants – including Johnson & Johnson and Merck – are also looking at investments in the AI sphere on th...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.